血浆生物标志物作为新发慢性肾脏病的风险因素
研究采用病例-队列设计,在无糖尿病且基线eGFR≥60 ml/min per 1.73 m2的MESA和REGARDS队列中评估新型血浆生物标志物与新发CKD的关联。MESA中KIM-1、suPAR、TNFR-1、TNFR-2和YKL-40均与新发CKD相关,REGARDS中仅TNFR-1和TNFR-2相关。可溶性TNFR-1和TNFR-2在两个队列中均一致与新发CKD相关。
要点
- 在MESA队列中,KIM-1、suPAR、TNFR-1、TNFR-2和YKL-40每升高2倍均与新发CKD相关。
- 在REGARDS队列中,仅TNFR-1和TNFR-2每升高2倍与新发CKD相关。
- 可溶性TNFR-1和TNFR-2在两个队列中均一致与新发CKD相关。
核心结论
- 在MESA和REGARDS两个队列的无糖尿病社区居住个体中,血浆可溶性TNFR-1和TNFR-2浓度与新发CKD一致相关。
研究设计与样本
- 采用病例-队列设计,在MESA和REGARDS队列中纳入无糖尿病且基线eGFR≥60 ml/min per 1.73 m2的参与者。
- 新发CKD定义为eGFR降至<60 ml/min per 1.73 m2且较基线下降≥40%。
- 检测血浆炎症/纤维化标志物TNFR-1、TNFR-2、MCP-1、YKL-40、suPAR及肾小管损伤标志物KIM-1。
- 使用针对病例-队列设计加权的Cox回归模型,校正CKD危险因素、eGFR和白蛋白尿后估计新发CKD的风险比(HR)。
- MESA中位随访9.2年,随机亚队列497人,新发CKD 163例;REGARDS中位随访9.4年,随机亚队列497人,新发CKD 497例。
主要发现
- MESA中,血浆KIM-1每升高2倍与新发CKD相关(校正HR 1.38 [95% CI 1.05-1.81])。
- MESA中,血浆suPAR每升高2倍与新发CKD相关(校正HR 1.96 [95% CI 1.10-3.49])。
- MESA中,血浆TNFR-1每升高2倍与新发CKD相关(校正HR 1.65 [95% CI 1.04-2.62]),TNFR-2每升高2倍与新发CKD相关(校正HR 2.02 [95% CI 1.21-3.38])。
- MESA中,血浆YKL-40每升高2倍与新发CKD相关(校正HR 1.38 [95% CI 1.09-1.75])。
- REGARDS中,血浆TNFR-1每升高2倍与新发CKD相关(校正HR 1.99 [95% CI 1.43-2.76]),TNFR-2每升高2倍与新发CKD相关(校正HR 1.76 [95% CI 1.22-2.54])。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Earlier identification of individuals at high risk of chronic kidney disease (CKD) may facilitate improved risk factor mitigation. METHODS: We evaluated the association of novel plasma biomarkers with incident CKD using a case-cohort design in participants without diabetes and with baseline estimated glomerular filtration rate (eGFR) ≥ 60 ml/min per 1.73 m2 in the Multi-Ethnic Study of Atherosclerosis (MESA) and Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohorts. Incident CKD was defined as development of eGFR < 60 ml/min per 1.73 m2 and ≥40% decline in eGFR from baseline. We measured plasma markers of inflammation/fibrosis-soluble tumor necrosis factor receptors (TNFRs) 1 and 2 (TNFR-1 and TNFR-2), monocyte chemotactic protein-1 (MCP-1), chitinase 3-like protein 1 (YKL-40), and soluble urokinase-type plasminogen activator receptor (suPAR)-and tubular injury (kidney injury molecule 1 [KIM-1]). Cox regression models weighted for the case-cohort design were used to estimate hazard ratios (HRs) of incident CKD after adjustment for CKD risk factors, eGFR, and albuminuria. RESULTS: In MESA (median follow-up of 9.2 years), there were 497 individuals in the random subcohort and 163 incident CKD cases. In REGARDS (median follow-up of 9.4 years), there were 497 individuals in the random subcohort and 497 incident CKD cases. Each 2-fold higher plasma KIM-1 (adjusted HR 1.38 [95% CI 1.05-1.81]), suPAR (1.96 [1.10-3.49]), TNFR-1 (1.65 [1.04-2.62]), TNFR-2 (2.02 [1.21-3.38]), and YKL-40 (1.38 [1.09-1.75]) concentrations were associated with incident CKD in MESA. In REGARDS, TNFR-1 (1.99 [1.43-2.76]) and TNFR-2 (1.76 [1.22-2.54]) were associated with incident CKD. CONCLUSION: Plasma concentrations of soluble TNFR-1 and TNFR-2 are consistently associated with incident CKD in nondiabetic community-living individuals in MESA and REGARDS.
引用
- Sarnak MJ, Katz R, Ix JH, et al. Plasma Biomarkers as Risk Factors for Incident CKD. Kidney Int Rep. 2022. PMID: 35812266. doi:10.1016/j.ekir.2022.03.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。